RE:RE:RE:RE:Remedies available to us minority shareholders So let’s sit back and think about this;
· TSO3 has spent allot of time and money perfecting the best in class sterilizer.
· TSO3 was so confident in their products that they terminated their channel partner agreement with 3M.
· The VP4 can handle up to a 34 kg load.
· The VP4 can do mixed loads.
· TSO3 was already working on studies for sterilizing endoscopes and duodenoscopes before the signed agreement with Getinge, this for the VP4 not the 125L. This tells us two things. One that they were in the process of preparing the scientific paper work to file with the FDA. Two TSO3 were confident that it was only a matter of time before receiving FDA approval.
· The agreement with Getinge had a clause in regards to minimum unit shipments to meet.
· TSO3 rec’d minimum 7 million dollars up front in the signing agreement.
Now let’s once again sit back and think about all this!
· It would only benefit both parties to share VP4 sales and install information as they happen. This would ensure TSO3 could meet actual increased demand for their product. Develop a list of where their product is being installed, this to follow up to gain data going forward. This data to be used in house only unless otherwise agreed to with Getinge.
· Once again, I have no problem with agreeing with Getinge on when they made the sales and installs going public, this as they form their sales strategy.
· TSO3 were entering into an agreement that would affect the future of the company. Do you not think it would be important to monitor when and where your product was being installed?